+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography



Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography



Journal of the Neurological Sciences 123(1-2): 44-51



Two of the more consistent findings in Alzheimer's disease are depressions in frontal and temporoparietal glucose metabolism and a loss of cholinergic neurons in the nucleus basalis of Meynert. Nonetheless, cholinergic replacement strategies have had only minimal therapeutic successes. Whether this situation reflects the limited contribution of cholinergic deafferentation to the intellectual decline or the meager ability of the pharmaceuticals tested to exert their intended pharmacologic action remains unclear. To address this question, the distribution of cerebral abnormalities found in untreated Alzheimer patients, as revealed by positron emission tomography following 18F-fluorodeoxyglucose, were compared with the pattern of functional changes produced by drugs that block or stimulate cholinergic function. Physostigmine was administered to 6 Alzheimer patients to increase brain cholinergic neurotransmission. The anticholinergic scopolamine, given to normal volunteers, was administered to 6 age-matched controls. These data were compared to those obtained from the same subjects while receiving placebo. Amnestic doses of the anticholinergic, scopolamine increased glucose metabolism by up to 20% (p lt 0.001) in all brain regions studied, except thalamus. This response contrasted with the metabolic reductions of up to 17% (p lt 0.01), especially in parietal and frontal association cortices, occurring in unmedicated Alzheimer patients. Maximum tolerated doses of the anticholinesterase, physostigmine, rather than tending to normalize abnormalities in these patients, further reduced cerebral metabolism (p lt 0.01) and increased metabolism in thalamus in a pattern inversely correlated (p lt 0.001) with that produced by scopolamine. These results fail to support a cholinergic basis for the abnormal metabolic pattern in Alzheimer's disease.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009012611

Download citation: RISBibTeXText

PMID: 8064320

DOI: 10.1016/0022-510x(94)90202-x


Related references

Physostigmine and scopolamine effects on glucose metabolism measured with positron emission tomography pet in human brain. Neurology 42(4 Suppl. 3): 348, 1992

The Baseline Pattern and Age-related Developmental Metabolic Changes in the Brain of Children with Autism as Measured on Positron Emission Tomography/Computed Tomography Scan. World Journal of Nuclear Medicine 17(2): 94-101, 2018

The in vivo distribution of carbon 11 scopolamine in human brain determined by positron emission tomography. Society for Neuroscience Abstracts 13(3): 1658, 1987

Muscarinic receptor imaging in human brain using carbon 11 scopolamine and positron emission tomography. Journal of Nuclear Medicine 29(5 Suppl.): 808-809, 1988

In vivo muscarinic cholinergic receptor imaging in human brain with carbon 11 scopolamine and positron emission tomography. Journal of Cerebral Blood Flow and Metabolism 12(1): 147-154, 1992

Neurochemical and metabolic effects of acute and chronic alcohol in the human brain: Studies with positron emission tomography. Neuropharmacology 122: 175-188, 2017

Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission?. Journal of Neuroscience 29(43): 13730, 2009

Dopamine metabolism in human brain measured in vivo with positron emission tomography. Journal of Neurology Neurosurgery and Psychiatry 49(4): 475, 1986

Dexamethasone effects in brain tumor patients measured with positron emission tomography. Neurology 34(3 Suppl. 1): 118, 1984

Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. Neuroimage 39(2): 555-565, 2008

Dopamine modulation of acetylcholine activity measured with positron emission tomography and 11C-benztropine in the human brain. Society for Neuroscience Abstracts 20(1-2): 25, 1994

Dopamine D2 receptors in normal human brain Effect of age measured by positron emission tomography and -raclopride. Nitsch, R M , Growdon, J H , Corkin, S , Wurtman, R J Annals of the New York Academy of Sciences; Alzheimer's disease: Amyloid precursor proteins, signal transduction, and neuronal transplantation 81-85, 1993

Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [11C]-raclopride. Annals of the new York Academy of Sciences 695: 81-85, 1993

Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. Archives of Neurology 50(5): 474-480, 1993

Brain oxygen utilization measured with oxygen-15 radiotracers and positron emission tomography: generation of metabolic images. Journal of Nuclear Medicine 26(4): 416-417, 1985